Table 4.

An 18-item questionnaire on the practice pattern of cosmetic botulinum toxin injections.

Q1.	What is your practice setting?
□	Private clinic
□	Secondary or tertiary referral hospital
Q2	How long have you been practicing botulinum toxin injections?
□	Less than 1 year
□	1–5 years
□	5–10 years
□	More than 10 years
Q3	What is the approximate percentage of patients who visit your office for cosmetic procedures and for disease treatment? (the total should be 100)
□	For cosmetic procedures: _______(%)
□	For disease treatment: _______(%)
Q4	What is the patient proportion, by age (years), of those who visit for cosmetic procedures? (total should be 100)
□	20–30 years: _______(%)
□	40–50 years: _______(%)
□	60 and over: _______(%)
Q5	Among those who receive cosmetic botulinum toxin injections, what is the treatment rate by site? (total should be 100)
□	Upper face: _______(%)
□	Midface: _______(%)
□	Lower face/neck: _______(%)
□	Body (trunk or extremities): _______(%)
Q6	What are the three most frequent indications among patients who receive cosmetic botulinum toxin injections?
□	Forehead wrinkles
□	Glabellar wrinkles
□	Crow’s feet
□	Bunny lines
□	Infraorbital wrinkles
□	Nasal tip elevation
□	Masseter hypertrophy
□	Smoker’s lines
□	Cobblestone chin and platysmal band
□	Shoulder contouring (Trapezius muscle injection)
□	1st: _________________________
□	2nd: _________________________
□	3rd: __________________________
Q7	Among those in their 20–30 years who receive cosmetic botulinum toxin injections, what is the rate of the procedure by site? (total should be 100)
□	Upper face: _______(%)
□	Mid face: _______(%)
□	Lower face/neck: _______(%)
□	Body: _______(%)
Q8	Among those in their 40–50 years who receive cosmetic botulinum toxin injections, what is the rate of the procedure by site? (total should be 100)
□	Upper face: _______(%)
□	Mid face: _______(%)
□	Lower face/neck: _______(%)
□	Body: _______(%)
Q9	Among the patients aged 60 years and older who receive cosmetic botulinum toxin injections, what is the rate of the procedure by site? (total should be 100)
□	Upper face: _______(%)
□	Mid face: _______(%)
□	Lower face/neck: _______(%)
□	Body: _______(%)
Q10	Please rank the following indications based on their popularity among patients who receive cosmetic botulinum toxin injections in the upper face.
□	Forehead wrinkles
□	Glabellar wrinkles
□	Periorbital wrinkles (“crow’s feet lines”)
□	1st: _________________________
□	2nd: _________________________
□	3rd: __________________________
Q11	Please rank the following indications based on their popularity among patients who receive cosmetic botulinum toxin injections in the midface.
	Nasal wrinkles (“bunny lines”)
□	Infraorbital wrinkles
□	Drooping nasal tip
□	1st: _________________________
□	2nd: _________________________
□	3rd: __________________________
Q12	Please rank the following indications based on their popularity among patients who receive cosmetic botulinum toxin injections in the lower face/neck.
□	Masseter hypertrophy
□	Vertical perioral wrinkles (“smoker’s lines”)
□	Chin creases (“cobblestone chin”)
□	Platysmal bands
□	1st: _________________________
□	2nd: _________________________
□	3rd: __________________________
Q13	Please rank the following indications based on their popularity among patients who receive cosmetic botulinum toxin injections in the body (trunk or extremities).
□	Shoulder contouring
□	Calf contouring
□	Upper arm contouring
□	1st: _________________________
□	2nd: _________________________
□	3rd: __________________________
Q14	When reconstituting a botulinum toxin product for wrinkle effacement, what amount of isotonic saline do you add for 100 units of type A botulinum toxin?
□	1 mL
□	2 mL
□	2.5 mL
□	4 mL
□	5 mL
Q15	Have you experienced cases suspicious of clinical resistance to botulinum toxin treatment?
□	No
□	Yes
Q16	What is your routine treatment interval for botulinum toxin injections?
□	2 months (or less)
□	3 months
□	4 months
□	5 months
□	6 months (or more)
Q17	What factor do you consider the most in choosing a botulinum toxin product?
□	Low price
□	Liquid formulation (pre-reconstituted botulinum toxin)
□	Low risk of antibody formation (low risk of clinical resistance)
□	Reliability (stability-constant potency, therapeutic efficacy)
Q18	What commercial product do you use the most?
□	Botox® Vistabel® (Allergan, USA)
□	Dysport®/Azzalure® (Galderma, Switzerland)
□	Xeomin®/ Bocouture® (Merz, Germany)
□	Meditoxin®/Neuronox® (Medy-Tox, Korea)
□	Botulax® (Hugel, Seoul, Korea)
□	Nabota®/Jeuveau® (Daewoong, Korea)